PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
1.260
-0.060 (-4.55%)
Apr 25, 2025, 4:00 PM EDT - Market closed

PDS Biotechnology Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2016 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
Net Income
-37.61-42.94-40.85-16.92-14.85
Upgrade
Depreciation & Amortization
0.060.060.050.010.02
Upgrade
Other Amortization
1.160.650.18--
Upgrade
Stock-Based Compensation
6.857.615.24.070.43
Upgrade
Other Operating Activities
0.271.185.240.280.18
Upgrade
Change in Accounts Payable
-5.35.76-0.09-0.110.22
Upgrade
Change in Other Net Operating Assets
-0.45-5.964.570.180.85
Upgrade
Operating Cash Flow
-35.03-33.64-25.71-12.49-13.15
Upgrade
Capital Expenditures
-0.03----
Upgrade
Investing Cash Flow
-0.03----
Upgrade
Long-Term Debt Issued
--25--
Upgrade
Long-Term Debt Repaid
-3.18-0.06---
Upgrade
Net Debt Issued (Repaid)
-3.18-0.0625--
Upgrade
Issuance of Common Stock
23.3716.4410.0148.8929.83
Upgrade
Repurchase of Common Stock
---0.27--
Upgrade
Other Financing Activities
---0.45--
Upgrade
Financing Cash Flow
20.1916.3834.2948.8929.83
Upgrade
Net Cash Flow
-14.87-17.268.5836.416.68
Upgrade
Free Cash Flow
-35.06-33.64-25.71-12.49-13.15
Upgrade
Free Cash Flow Per Share
-0.96-1.09-0.90-0.49-0.79
Upgrade
Cash Interest Paid
3.563.540.85--
Upgrade
Levered Free Cash Flow
-23.34-21.17-16.47-9.04-7.68
Upgrade
Unlevered Free Cash Flow
-21.57-19.19-15.83-9.04-7.68
Upgrade
Change in Net Working Capital
5.75-0.04-4.97-0.25-1.17
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q